



Florida Cancer Data System

A JOINT PROJECT OF THE SYLVESTER COMPREHENSIVE CANCER CENTER AND THE FLORIDA DEPARTMENT OF HEALTH

FCDS 2013-2014 QUALITY IMPROVEMENT EDUCATION AND TRAINING

FCDS Webcast Series

Steven Peace, BS, CTR

Mayra Espino, BA, RHIT, CTR

October 24, 2013



AMERICAN COLLEGE OF SURGEONS
Cancer Programs




Continuing Education Hours

NCRA CEU #	Date	Event	Sponsor	CEU Hrs
2013-114	7/25/2013 - 7/26/2013	FCDS Annual Conference, Sunrise, FL	FCDS	8.25
2013-115	8/22/2013	Webcast : "What's New for 2013 and More - Annual Meeting Review"	FCDS	2
2013-116	9/19/2013	Webcast: "Lung Neoplasms-Background/Anatomy/Risk Factors/MPH Rules/CS02.04/SSF/Tx"	FCDS	2
2013-117	10/24/2013	Webcast : "New Developments in FCDS Quality Improvement and Education and Training"	FCDS	2
2013-118	11/21/2013	Webcast: "Breast Neoplasms-Background/Anatomy/Risk Factors/MPH Rules/CS02.04/SSF/Tx"	FCDS	2
2013-119	12/12/2013	Webcast : "Colon/Rectum Neoplasms- Background/ Anatomy/Risk Factors/MPH Rules/CSv02.04/SSF/Tx"	FCDS	2
2013-120	1/17/2014	Webcast : "FCDS Learning Management System – What's New for 2014 and Version 2.0 of FCDS LMS"	FCDS	2
2013-121	2/21/2014	Webcast : "Lymphoid Neoplasms - Background/Anatomy/Risk Factors/MPH Rules/CSv02.04/SSF/Tx"	FCDS	2

Presentation Outline

- **Rule Makers for National Data Collection**
- **NPCR Program Standards 2012-2017**
- **NAACCR Certification Criteria**
- **FCDS Data Quality Program**
 - Data Quality Goals
 - Data Quality Policy
 - Data Quality Activities
 - Data Quality Audits
 - Data Quality Reports
- **FCDS Education and Training Program**
- **FCDS “Future Vision”**
- **Current FCDS QC Issues**



Rule Makers for National Data Collection

CDC NPCR – FCDS Participates in NPCR

- State/Central Registries – 98% of US Population – State/Federal Legislation
- Data Acquisition Manual


ACoS Commission on Cancer

- ACoS Cancer Programs – CoC Cancer Program Standards - Voluntary
- National Program for Breast Centers – NAPBC Standards – Voluntary
- FORDS

NCI SEER Program


- SEER Registries – 28% of US Population – State/Federal Legislation
- 26 percent of African Americans, 41 percent of Hispanics, 43 percent of American Indians and Alaska Natives, 54 percent of Asians, and 71 percent of Hawaiian/Pacific Islanders.
- SEER Program Manual

NPCR Program Standards, 2012-2017



NPCR Program Standards, 2012-2017

All funded programs must meet the following standards:



- Legislative Authority
- Administration
- Data Collection, Content, and Format
- Electronic Data Exchange
- Data Completeness/Timeliness/Quality
- Linkages
- Data Quality Assurance and Education
- Data Use and Data Monitoring
- Data Submission
- Collaborative Relationships

NPCR Program Standards, 2012-2017

- Data being evaluated for the National Data Quality Standard (formerly known as the 24-Month Standard), must meet the following five data quality criteria:
 - Data are **95% complete** based on observed-to-expected cases as computed by CDC.
 - There are **3%** or fewer **death-certificate-only** cases.
 - There is a **1 per 1,000** or fewer **unresolved duplicate** rate.
 - The **maximum percent missing** for critical data elements are:
 - **2%** age
 - **2%** sex
 - **3%** race
 - **2%** county
 - **99% pass** a CDC-prescribed set of **standard edits**.



NPCR Program Standards, 2012-2017

- Data being evaluated for the **Advanced National Data Quality Standard** (formerly known as the **12-Month Standard**), must meet the following data quality criteria:
 - Data are **90% complete** based on observed-to-expected cases as computed by CDC.
 - There is a **2 per 1,000** or fewer **unresolved duplicate** rate
 - The **maximum percent missing** for critical data elements are:
 - 3% age
 - 3% sex
 - 5% race
 - 3% county
 - **97% pass** a CDC-prescribed set of **standard edits**.



NPCR Program Standards, 2012-2017

- Data Quality Assurance and Education
 - The central cancer registry has an overall program of quality assurance that is defined in the registry operations manual.
 - The quality assurance program consists of, but is not limited to:
 - A designated certified tumor registrar (CTR) responsible for the quality assurance program.
 - Quality assurance activities should be conducted by qualified experienced CTR(s) or CTR-eligible staff.
 - At least once every 5 years, a combination of case-finding and re-abstracting audits from a sampling of source documents are conducted for each hospital-based reporting facility, and may include external audits by CDC or SEER.
 - Data consolidation procedures are performed according to the central cancer registry protocol and nationally accepted abstracting and coding standards as available.
 - Audits of a routine sample of consolidated cases at the central cancer registry.
 - Feedback is provided to reporting sources on data quality and completeness.

NPCR Program Standards, 2012-2017

- Data Quality Assurance and Education
 - The central cancer registry has an overall education program that is defined in the registry operations manual.
 - The education program consists of, but is not limited to:
 - Training for central cancer registry staff and reporting sources to assure high quality data.
 - A designated education/training coordinator who is a qualified, experienced CTR.
 - Where feasible, the education/training coordinator may be regionally-based, such that CDC-NPCR applicants collaborate to identify one applicant to provide the education/training coordinator for activities to be carried out in the full region.

Annual Report to the Nation




NAACCR Gold Certification Criteria



- Case ascertainment = **95% or higher completeness.**
- **< 3%** of cases are reported by **Death Certificate Only.**
 - **< 0.1% duplicate case reports** are in the file.
 - **100% error-free data.**
 - **< 2% of cases are missing age, sex, or county.**
 - **< 3% of cases are missing race.**
- The file is submitted to NAACCR for evaluation within 23 months of the close of the diagnosis year under review.

Gold and Silver Level Certification Status of NAACCR U.S. Cancer Registries for 2010 Data




The FCDS Data Quality Program



FCDS Data Quality Pyramid



FCDS Quality Improvement



Foundation - Communication/Education

- Technical Answers by Telephone or E-mail
- Email (E-Mail Blast for Urgent or Timely Information)
- Email (Individual for questions or if you are having problems)
- FCDS IDEA (QC Review, Edits/Corrections, Documentation)
- FCDS RECAP – FCDS Internal Tool for Data Processing
- FCDS On-Line Abstractor Training Course
- FCDS Annual Meeting – face-to-face
- FCDS Memo – every two months
- FCDS Web Broadcasts



FCDS Data Quality Program - Goals

- **Goals:**
 - Population-Based Reporting
 - Highest Quality Data Possible
 - Confidentiality, Privacy, Data Security
- **Objectives:**
 - Improve Communications
 - Improve Feedback Loop
 - Improve Completeness
 - Improve Data Quality
 - Improve Usefulness
 - Improve Timeliness
 - Improve Education
 - Improve Reports
 - Improve Training




FCDS Data Quality Program - Goals

- Establish, perform, manage Quality Improvement/Quality Control projects
- Apply national and internal standards for data collection, aggregation, etc
- Systematically measure performance against those standards
- Assess outcomes and performance measures
- Develop measurement and evaluation tools
- Develop quality enhancement strategies
- Assess registry needs and satisfaction
- Monitor completeness, quality and timeliness
- Provide education and training to improve data quality




FCDS Data Quality Program - Methods

- Florida Cancer Reporting Legislation
- Florida Public Health Administration Rules
- FCDS Policy and Procedures (FCDS DAM)
 - Internal Policy and Procedures
 - External Policy and Procedures
 - Monitoring Data Quality and Performance
- Quality Assurance / Quality Improvement Activities
 - Monitor operations workflow and data quality and take action to improve future quality, maximizing correct reporting and characterizing the reporting process in measurable terms.
- Perform External Linkage to Improve Data
 - Obtain and/or validate data items by linking central cancer registry databases with clinical and non-clinical state and national databases
 - Using death certificate data to add missing vital status and race
 - Using claims data to complete first course of treatment data



FCDS Data Quality Program - Methods

- **FCDS Policy**
 - FCDS Abstractor Code Requirement
 - FCDS EDITS Requirement
 - Text Documentation Requirement
 - Deadlines and IT Security
- **FCDS Procedures**
 - FCDS IDEA – Communication/Transmission
 - FCDS Internal Data Processing Monitoring
 - FORCES/CORRECTIONS/DELETIONS
 - Patient and Tumor Linkage & Consolidation
- **FCDS Monitoring / Audits**
 - Audits for Completeness
 - Audits for Timeliness
 - Audits for Accuracy
- **FCDS Data Quality Reports**
 - Quarterly/Annual Status Reports
 - Ad Hoc Reports
 - Audit Results



FCDS Data Quality Program - Policy


Official Internet Site of the Florida Legislature

December 6, 2012

Search Statutes:

[Home](#)
[Senate](#)
[House](#)
[Citorator](#)
[Statutes, Constitution,
& Laws of Florida](#)
[Florida Statutes](#)
[Search Statutes](#)
[Search Tips](#)
[Florida Constitution](#)
[Laws of Florida](#)
[Legislative & Executive
Branch Lobbyists
Information Center](#)
[Joint Legislative
Committees &
Other Entities](#)
[Historical Committees](#)
[Legislative Employment
Registore](#)
[Links](#)

Select Year:

The 2012 Florida Statutes

[Title XXIX](#)
[Chapter 381](#)
[View Entire Chapter](#)

PUBLIC HEALTH PUBLIC HEALTH: GENERAL PROVISIONS

381.0031 Epidemiological research; report of diseases of public health significance to department.—

(1) The department may conduct studies concerning the epidemiology of diseases of public health significance affecting people in Florida.

(2) Any practitioner licensed in this state to practice medicine, osteopathic medicine, chiropractic medicine, naturopathy, or veterinary medicine; any hospital licensed under part I of chapter 395; or any laboratory licensed under chapter 483 that diagnoses or suspects the existence of a disease of public health significance shall immediately report the fact to the Department of Health.

(3) An animal control officer operating under s. [828.27](#), a wildlife officer operating under s. [379.3311](#), or an animal disease laboratory operating under s. [585.61](#) shall report knowledge of any animal bite, diagnosis of disease in an animal, or suspicion of a grouping or clustering of animals having similar disease, symptoms, or syndromes that may indicate the presence of a threat to humans.

(4) The department shall periodically issue a list of infectious or noninfectious diseases determined by it to be a threat to public health and therefore of significance to public health and shall furnish a copy of the list to the practitioners listed in subsection (2). The list shall be based on the

Interpreter Services for the Hearing Impaired

FCDS Data Quality Program - Policy

FCDS Abstractor Code – A National Model for QC



FCDS Data Quality Program - Policy

FCDS Text Documentation Requirements

DATA ITEMS REQUIRING COMPLETE TEXT DOCUMENTATION	
Date of DX	RX Summ – Surg Prim Site
Seq No	RX Summ – Scope Reg LN Surgery
Sex	RX Summ – Surg Oth Reg/Distant
Primary Site	RX Date – Surgery
Subsite	RX Summ – Radiation
Laterality	Rad Rx Modality
Histologic Type	RX Date – Radiation
Behavior Code	RX Summ – Chemo
Grade	RX Date – Chemo
	RX Summ – Hormone
CS Tumor Size	RX Date – Hormone
CS Ext	RX Summ – BRM/Immunotherapy
CS Tumor Ext/Eval	RX Date – BRM/Immunotherapy
Regional Nodes Positive	RX Summ – Transplant/Endocrine
Regional Nodes Examined	RX Date – Transplant/Endocrine
CS LN	RX Summ – Other
CS LN Eval	RX Date - Other
CS Mets	
CS Mets Eval	Any Unusual Case Characteristics
All FCDS Req'd SSFs	Any Pertinent Patient/Family History

FCDS Data Quality Program - Policy

FCDS Text Documentation Requirements

APPENDIX L FCDS TEXT DOCUMENTATION REQUIREMENTS

Text documentation is an essential component of a complete electronic abstract and is heavily utilized in quality control, to validate data at time of FCDS and NPCR Audits, and for special studies. Text documentation is required to justify coded values and to supplement information not transmitted with coded values. **FCDS recommends that abstractors print and post this document for easy reference.** Adequate text is a data quality indicator and will be major part of QC.

Text documentation should always include the following components:

- Date(s) – include date(s) references – this allows the reviewer to determine event chronology
- Date(s) – note when date(s) are estimated [i.e. Date of DX 3/15/2011 (est.)]
- Location – include facility/physician/other location where the event occurred (test/study/treatment/other)
- Description – include description of the event (test/study/treatment/other) – include positive/negative results
- Details – include as much detail as possible – document treatment plan even if treatment is initiated as planned
- Include “relevant-to-this-person/cancer” information only – edit your text documentation
- DO NOT REPEAT INFORMATION from section to section
- DO USE Standard Abbreviations (Appendix B)
- DO NOT USE non-standard or stylistic shorthand
- Enter “N/A” or “not available” when no information is available related to any specific text area.

FCDS Data Quality Program - Policy

FCDS Text Documentation Requirements

APPENDIX L FCDS TEXT DOCUMENTATION REQUIREMENTS	
Text Data Item Name	Text Documentation Source and Item Description
NAACCR Item # Field Length	<i>FCDS Required Text Documentation</i> Example:
Text - Operative Report	Enter text information from surgical operative reports (not diagnostic needle, incisional biopsy). Include observations at surgery, tumor size, and extent of involvement of primary or metastatic sites. <i>Date of procedure, facility where procedure was performed, type of surgical procedure, detailed surgical findings, documentation of residual tumor, evidence of invasion of surrounding areas</i>
NAACCR Item #2560 Field Length = 1000	Example: 4/12/11 (Hosp xyz) right colon resection - Pt was found to have extensive disease in the pelvis (carcinomatosis) and resection was aborted
DX Text - Pathology	Enter text information from cytology and histopathology reports. <i>Date of specimen/resection, facility where specimen examined, pathology accession #, type of specimen, final diagnosis, comments, addenda, supplemental information, histology, behavior, size of tumor, tumor extension, lymph nodes (removed/biopsied), margins, some special histo studies</i>
NAACCR Item #2570 Field Length = 1000	Example: 2/5/11 (Hosp xyz) – Path Acc # - Rectum: Final Dx: adenoca, 2.5cm, ext. to pericolic fat. 1/22 lymph nodes + , margins neg, S100 stain is positive (melanoma, sarcoma)
DX Text - Staging	Enter Details of Collaborative Stage and other stage information not already entered in other text areas. Include specific information on Tumor Size, Extension of Primary Tumor, Metastatic Sites, etc. <i>Organs involved by direct extension, size of tumor, status of margins, sites of distant metastasis, special consideration for staging, overall stage, etc. Text for SSF documentation if not under Labs.</i>
NAACCR Item #2600 Field Length = 1000	Example: 2/15/11 - T2aN1a per path, distant mets in lungs, ER/PR neg, HER2 neg by IHC method
RX Text - Surgery	Enter text describing the surgical procedure(s) performed as part of 1 st course treatment. <i>Treatment plan, date surgery performed, type of procedure, facility where surgery was performed</i>
NAACCR Item #2610 Field Length = 1000	Example: 2/15/11 (Hosp xyz) - rt breast mrm w/ax ln dissection

FCDS Data Quality Program - Policy

FCDS EDITS Metafile and EDITS PASS Requirement

FCDS transitioned from an Oracle-based edits program written by FCDS contractors to the National Standard EDITS Metafile in September 2010.

Standard EDITS include Field-Item, Inter-Item and Intra-Item Edits

- Edits validate codes, crosscheck relationships between data items (male with prostate cancer) and checks for blank fields.
- The FCDS EDITS Metafile was created for Florida, specifically to accommodate the reporting of historical cases among other FCDS special coding requirements
- FCDS has also included edits in the metafile for common abstracting errors identified through re-abstracting audits.

FCDS Data Quality Program - Policy

- Deadlines and Data Monitoring Policy and Procedures
- Confidentiality of Protected Health Information
- IT Security Policy and Procedures
- Patient Privacy and HIPAA
- No Paper Policy
- Other



FCDS Data Quality Program - Procedures


- FCDS EDITS Metafile
- FCDS Correction / FORCE / Delete
- FCDS QC Review of Every 25th Record – Visual Editing
- Patient and Tumor Linkage and Consolidation Procedures
- FCDS Audit Findings Link Back to Education
- FCDS Data Use Link Back to Procedures

FCDS Data Quality Program - EDITS



Standard Sources for EDITS

- NCI SEER
- CDC NPCR
- ACOS COC
- Other States
- Collaborative Stage
- FCDS for Florida-Specific
- NAACCR EDITS Working Group




Florida Cancer Data System




FCDS EDITS Check For Conditions





- Blank Field Checks – Single Item Edit
- Valid Code Checks – Single Item Edit
- Valid Date Checks – Single Item Edit
- Inter-Field Edits – Relationships Between Items
- Inter-Record Edits – Relationships Between Cases
- CS Edits – Core
- CS Edits – Staging
- CS Edits – SSFs
- Inter-Field CS and Other Item Edits (scope, surg)
- Link CS Stage and SSF Data to Treatment Plan

Number of Edits Over Time



Total Edit Failures Over Time



Category 	Error #	Warning 	Force 	Description 
Age Edits	81	N	Y	Invalid Morphology for patient over age 5 based on ICD-O-3
Age Edits	82	N	Y	Invalid Site for patient under age 15
Class of Case Edits	149	N	N	Class of Case equal 38 (autopsy only) or 49 (DCO) and Vital Status not equal 0 (dead)
Class of Case Edits	150	N	N	Class of Case equal 5 and all Rx not equal 00 or 0
Collaborative Staging Edits	1	N	N	There is missing data (blank field) or invalid characters exist in the data for this data item
Collaborative Staging Edits	287	N	N	If CS Extension is 950, CS Lymph Nodes cannot = 000 and CS Mets at DX cannot be 00
Dx Confirmation Code Edits	219	N	Y	ICD-O-3 Behavior 2 requires Dx Confirmation 1, 2, or 4
Grade Code Edits	204	N	N	Grade must = 6 for this ICD-O-3 Morph code
Grade Code Edits	834	N	N	Grade should be coded to Implied Grade for this histology
Grade Code Edits	841	N	N	Grade is invalid
Invalid Codes Edits	10	N	N	ICD-O-3 Morphology not valid
Invalid Codes Edits	12	N	N	ICD-O-2 Morphology not valid
Invalid Codes Edits	102	N	N	Facility Code not valid
Probable Duplicate Edits	106	N	Y	Probable duplicate detected in master file
Sequence Edits	40	N	Y	Sequence greater than zero with Ill-Defined primary site, Ill-Defined Lymphoma, or Ill-Defined Leukemia
Sex/Site Edits	11	N	N	Sex not valid with Site
Site Code Edits	52	N	N	Site equals C50.* and Morphology equals 8521
Site/Morphology Edits	190	N	Y	ICD-O-3 Morphology not valid with Site or not reportable to FCDS
Site/Morphology Edits	207	N	Y	ICD-O-3 morphology cannot equal 8521/3 when site = C50.*. Verify morphology code
Therapy and Date Edits	268	N	Y	Breast, Prostate - Transplnt/Endocr Surg Rx Date must be less than 365 days after Diagnosis Date
Therapy and Date Edits	269	N	Y	Transplnt/Endocr Surg RX Date must be less than 240 days after Diagnosis
Warnings	358	Y	N	WARNING: Other Rx is greater than 0 or less than 9
Warnings	359	Y	N	WARNING: Please verify this case is reportable. Check Sect. I of the FCDS DAM for reportability guidelines
Warnings	989	Y	N	WARNING: NPI Number Invalid or assigned after last registry update

FCDS and National EDITS – Coming Soon!

- Updates to SEER Site/Type Table
 - 2013 Hematopoietic and Lymphoid Neoplasm Site/Type
 - 2014 Hematopoietic and Lymphoid Neoplasm Site/Type
 - 2015 ICD-O-3 Updates – New Histology Codes and New Site/Type
 - General Updates to Site/Type Combinations
- Increasingly Complex Inter-Field EDITS
- Treatment EDITS linked to cancer profile
- Treatment EDITS linked to cancer stage
- Clinical Edit Checks
 - NCCN/ASCO Guidelines
 - NCDB Submission Edits
 - RQRS (Rapid Quality Reporting System)
 - CP3R (Cancer Program Practice Profile Reports)



Staying Current - FCDS EDITS

- Understand FCDS EDIT and what each is designed to do
- Review FCDS EDITS Messages – make them more clear
- Identify FCDS EDITS that are “FORCEABLE”
- Understand FCDS EDITS/CORRECTION/FORCE Process
- Understand FCDS FC/QC responsibilities and expectations
 - External FCDS EDITS Metafile to be used by Registrars
 - Internal FCDS EDITS Metafile used by FCDS
 - FCDS Metafile Excel Sheet documenting changes
- Registrar Interest in Learning How to Use Edit Writer



Staying Current - FCDS EDITS

<http://fcds.med.miami.edu/inc/downloads.shtml#fcdsdatafiles>

What's New / Downloads

FCDS Data Files

- [Independent Contractor List \(comma separated text file\)](#) This list of independent contractors is provided as a courtesy and should not be considered a complete list (as the list is updated only twice per year). Additionally, the Florida Cancer Data System makes no recommendations about the individual's abilities or skills and takes no responsibility for the quality of their work. Inclusion on this list is by request of the independent contractor.
- [Zip code, Fips County, Florida City Name Verification file \(comma separated text file\)](#) This can be used by abstracting vendors to lower the number of county/zip/city errors for abstracts submitted to FCDS. The [USPS Zip/County/Address Lookup Page](#) has the very latest zipcodes.
- [Current list of FCDS Edit messages as a comma separated file.](#) This link downloads the latest FCDS Edit Messages with Force/Warning flags. Sorted by category/edit#.
- FCDS/NAACCR EDITs Metafile - Updated metafiles will be posted here when there are corrections/changes, so check this page for new versions:
 - [13.0A Metafile \(July 28\), posted 08/8/2013 10:50am, Metafile changes](#)



Staying Current - FCDS EDITS Metafile

Metafile Version	Modification Date	Edit	Edit Name	Comments
			Green = deleted	
			Yellow = new edits	
			Blue = edit name/field name changes	
13A				
13A	06/25/13	1351	Addr at DX--Country (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1352	Addr at DX--Country, Date of Diagnosis (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1353	Addr at DX--Country, State (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1354	Addr Current--Country (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1355	Addr Current--Country, Date of Diagnosis (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1356	Addr Current--Country, State (NAACCR)	New edit - added to both edit sets
13A	06/25/13	0009	Birthplace (SEER POB)	DELETED from both FCDS edits sets
13A	06/25/13	1357	Birthplace--Country (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1358	Birthplace--Country, Date of Diagnosis (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1359	Birthplace--Country, State (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1360	Birthplace--State (NAACCR)	New edit - added to both edit sets
13A	06/25/13	1361	Birthplace--State, Date of Diagnosis (NAACCR)	New edit - added to both edit sets
13A	06/25/13	0969 0970	CS Ext, LN, Mets at DX, SSF 1, Retinoblastoma (CS)	Added SEER IF number (IF349)
13A	06/25/13	0971 0972	CS Ext, LN, Mets at DX, SSF 3, Prostate (CS)	Added SEER IF number (IF350)
13A	06/25/13	1367	CS Ext, Surg, TS/Ext Eval, Prostate (CS)	New edit - added to both edit sets
13A	06/25/13	1369, 1370	CS Ext,TS/Ext Eval, SSF 1, MelanomaConjunc (CS)	New edit - added to both edit sets
13A	06/25/13	0287, 0447, 0451, 0482, 1101- 1103	CS Extension, CS Lymph Nodes, CS Mets at DX (CS)	Updated last paragraph of description: changed "For all other sites" to "If schema is not Breast, Bladder, KidneyRenalPelvis, Urethra or UrinaryOther".
13A	06/25/13	1368	CS Extension, Histology, Grade, Thyroid (CS)	New edit - added to both edit sets
13A	06/25/13	1371	CS Extension, SSF 1, Conjunctiva Schema (CS)	New edit - added to both edit sets
13A	06/25/13	1372	CS Extension, SSF 1, MelanomaConjunctiva (CS)	New edit - added to both edit sets
13A	06/25/13	1373, 1374	CS Extension, SSF 2, Lung Schema (CS)	New edit - added to both edit sets
13A	06/25/13	1376	CS Extension, SSF 2, MelanomaChoroid (CS)	New edit - added to both edit sets
13A	06/25/13	1377	CS Extension, SSF 2, MelanomaCiliaryBody (CS)	New edit - added to both edit sets

Master List(s) – FCDS EDITS

Category	Error Code	Warning Flag	Force Flag	Description
Age Edits	81	N	Y	Invalid Site and Morphology for patient over age 5 based on ICD-O-2
Age Edits	82	N	Y	Invalid Site for patient under age 15
Class of Case Edits	149	N	N	Class of Case equal 38 (autopsy only) or 49 (DCO) and Vital Status not equal 0 (dead)
Class of Case Edits	520	N	N	If Class of Case equal 38 (autopsy only), then Date of Diagnosis and Date of Last Contact must be the same date.
Collaborative Staging Edits	287	N	N	If CS Extension is 950, CS Lymph Nodes cannot = 000 and CS Mets at DX cannot be 00
Collaborative Staging Edits	288	N	N	If CS schema is not KaposiSarcoma, MelanomaSkin, Conjunctiva, MelanomaConjunctiva, MelanomaChoroid, Melanomalris, MelanomaCiliaryBody, or LymphomaOcularAdnexa: If CS Extension = 950, then CS Tumor Size must = 000.
Grade Code Edits	1263	N	N	Unknown Primary Site (C809), Grade must = 9
Grade Code Edits	1300	N	N	Grade must = 5, 8, or 9 for this ICD-O-3 Morph code
Invalid Codes Edits	10	N	N	Site not valid
Invalid Codes Edits	14	N	N	Abstractor code not valid
Morphology Code Edits	839	N	Y	Histology is not valid
Morphology Code Edits	840	N	Y	Invalid Histology for in situ
Out of Range Edits	19	N	N	County Residence Current out of range (11-77, 88 or 90) or not numeric
Out of Range Edits	22	N	N	Hispanic Origin is out of range (0 through 7 or 9)
Probable Duplicate Edits	106	N	Y	Probable duplicate detected in master file
Sequence Edits	40	N	Y	Sequence greater than zero with III-Defined primary site, III-Defined Lymphoma, or III-Defined Leukemia
Sequence Edits	63	N	N	If Date of 1st Contact is less than 1981, Sequence Number--Hospital cannot = 00 or 60
Therapy and Date Edits	113	N	N	If Surgery Primary Site = 00 and Scope Reg LN Surg = 0 and Surg Oth/Reg/Dist = 0 then Surg Date must equal 00000000
Therapy and Date Edits	119	N	N	If RX Summ--Chemo = 00, 82, or 85-87 (chemo not given) then RX Date--Chemo must be blank and RX Date--Chemo Flag field must = 11 (no chemo).
Warnings	60	Y	N	WARNING: Other Rx is greater than 0 or less than 9
Warnings	359	Y	N	WARNING: Please verify this case is reportable. Check Sect. I of the FCDS DAM for reportability guidelines

2012 Corrections/Deletions/FORCES

All Cases Processed	Receipt Date 2012	% of Total Cases
Good	182,449	93.8%
Corrected	5,146	2.6%
Forced	2,866	1.5%
Deleted	1,965	1.0%
Total Processed	194,426	100%

2012 QC Review Summary

QC Review/Visual Edit	# Cases	% of Total
Total Cases Processed	194,426	100%
Total Cases Selected	10,007	4.6% of ALL
No Additional Review	7,396	74% of Sample
QC Review Follow-Back	2,611	26% of Sample
2 nd Review - No Change	834	8.3%
2 nd Review - FORCE	50	0.5%
2 nd Review - CORRECT	1,693	16.9%
2 nd Review - DELETE	34	0.3%

Visual Editing of Cases

- **Rationale for Visual Editing**
- **Standards for Visual Editing**
- **Timing for Visual Editing**
 - New Abstractor Review
 - Automated QC Review
 - Individual Case Corrections/Forces
 - Case Consolidation
 - Special Studies
 - Audits



FCDS Data Quality Program – Every 25th

FCDS QC Visual Review - Every 25th Record

- 2012 Added All Male Breast and All Pediatric Neoplasms to QC Review

GOAL: Evaluate whether or not the case makes sense as coded or is something missing or unusual that edits would not catch. Does the case make sense as coded or is something missing or “off” with case as coded.

By selecting one of every 25th records received plus male breast and all pediatric cases, FCDS visually edits at least 5% of the total cases submitted each year. Other cases visually edited are cases being evaluated for FORCES, Corrections, Special Studies, and During Data Use (up to 10% of annual cases).

- The QC Abstract Review Process is a 3-step process - fully automated.
 - **Step 1: initial review**
 - **Step 2: feedback to/from the registrar with opportunity to defend coding**
 - **Step 3: third party mediation assesses the first reviewer’s findings, the facility’s comments, any recommended corrections, or feedback and come to a final determination on the case – the mediators decision is final**
- **Records with discrepant data must be resolved by the reporting facility.**
- **“Agree”, “OK”, “Done” are NOT Acceptable Responses to Inquiries**

Visual Review – What We Are Seeing

- **Treatment Documented in Text BUT NOT CODED**
- If you get a QC Review asking you to code treatment and in your system it is coded – FCDS didn't get the code – you must contact your vendor to see why not transmitted.
- **Replies on QC Review still are lacking clear answers**
- **“ok” – “updated abstract” – “agree” are NOT answers.**
- Replies on QC Change in Primary Site **MUST** include complete **RESTAGING** – this is often overlooked and must not only be restaged – but must be in text fields.
- **Treatment Planned versus Treatment Delivered - CONFIRM**

Visual Review – What We Are Seeing

- You CAN copy and paste from EMR – BUT PLEASE EDIT the copy and paste and be sure it is relevant / complete AND be sure that you include the FINAL DIAGNOSIS.
- EDIT – EDIT – EDIT – some of you ramble and it does not make sense or you copy and paste without reading text
- Some facilities not coding complete first course treatment and FCDS knows patient had additional surgery because we get the e-path report from your facility showing txs.
- Okay to save time – but please do not sacrifice quality or complete reporting or it will come back to you with questions

Visual Review – The Panoramic View

- Are there many blank spaces?
- Is code 9 (unknown) used frequently?
- Are there other numeric red flags (.8, 88, 8)?
- Are all dates in logical order?
- Are text fields significantly different from coded field translations?
- Is treatment appropriate for site and stage?
- Is there logical progression from stage at initial diagnosis to recurrence and recurrence sites?
- Does the abstract tell a complete story?

Visual Review – Demographic Items

- Surname – Spanish origin
- Race – Surname – Place of birth
- Area code – County
- Date of birth – Date of diagnosis
- Sex – Name
- Sex – Primary site
- Age – Occupation
- Age – Marital status
- Age – Primary site and histology
- Address – Place of diagnosis
- City -- County



Visual Review – Diagnosis Items

- Primary site code – Text
- Histology code – Text
- Site – Laterality – Histology
- Behavior – Diagnostic confirmation
- Dx confirmation – Histology > 8000
- Are dates in logical sequence?
- Is Dx date the earliest documented?
- Class of case – Facility referred to/from
- Dx date – Place of diagnosis
- Site – Type of admission
- Sequence no. – Other primaries



Visual Review – Staging Items

- Stage – Primary site
- CS codes – Procedures text
- CS Extension – Summary stage – cT / pT
- CS Extension – SSFs (by site)
- Age – Pediatric stage
- CS Lymph Nodes – Summary stage – cN / pN
- CS Lymph Nodes – SSFs (by site)
- Tumor size > 100
- Nodes pos/exam – Surgery
- CS Mets at Dx – Summary stage – cM / pM
- Staging basis – Dates of treatment



Visual Review – Treatment Items

- Planned first course listed?
- Treatment – Primary site – Stage
- Treatment code – Procedure name
- Treatment – Facility referred from/to
- Surgery – Operative findings text
- Surgery – Pathology text
- Date 1st surg – Date most definitive surg
- Date most definitive surg – Date surg discharge
- Surg prim site – Margins
- Surg prim site – Scope reg LN
- Surg prim site – Reason no surg






Visual Review – Treatment Items

- Surgery – Radiation – RT/surgery seq
- Date RT start – Date RT end
- Location of RT – Facility referred from/to
- RT treatment volume – Reason no RT
- RT treatment volume – Boost volume
- Systemic tx – Primary site
- Systemic tx date – Chemo – Hormone – Immunotherapy
- Systemic tx date – Date most definitive surgery – Systemic/surgery sequence
- Hematologic Transplant & Endocrine Procedure – Primary site
- RT treatment volume – Palliative care



Patient and Tumor

Match, Link & Consolidate




BEST INFORMATION AVAILABLE FROM ALL SOURCES

Patient and Tumor Match, Link & Consolidate


- Electronic edits, Visual Editing, Patient and Tumor Matching
- Comparison of individual data and data items
- Records received are checked for duplicate reporting
- Multiple reports for same patient are merged to capture most complete demographic data
- Multiple reports for same patient are checked for new tumors (same vs. new primary)
- Multiple reports for the same tumor are merged to capture most complete diagnostic, staging and treatment data

Patient and Tumor Match, Link & Consolidate



FCDS Data Quality Program - Audits

- Introduction to FCDS Audits – Topic Selection / Protocol
- Audits to Assess Completeness
- Audits to Assess Timeliness
- Audits to Assess Accuracy
- Reconciliation Process
- External Audits
- Other



FCDS Data Quality Program - Audits

- Annual audits
 - Completeness
 - Timeliness
 - Data Quality/Validation
- Targeted audits
 - Identify extent of specific problems
 - Identify individual data collector training needs
 - Review and improve data quality in problem areas
- Random audits
 - Validate central registry data for research purposes
 - Identify unknown problem areas
 - Identify general data collector training needs
 - Review and improve data quality in unknown areas




FCDS Data Quality Program - Audits

- **Study/Audit Timeline**
- **Protocol Template**
 - Introduction
 - Purpose
 - Description of Study
 - Sample size
 - Study population
 - Audit Notification
 - Audit Procedures
 - Reconciliation Procedures
 - Data Analysis plan
 - Feedback plan
 - Recommendations
- **Protocol Review**



Completeness



The NPCR–AERRO scope diagram shown above is a simple flow diagram that identifies hospital and central registry data sources in a ranked order, based on the quantity of useful data that are available and reported to the central cancer registry.

Completeness

- Casefinding is not just a Discharge Diagnosis Index
- Pathology Casefinding is Critical because HIM misses 10% or more of all cases because they don't have info available at time of discharge or for ambulatory surgeries
- FCDS will soon be conducting e-path completeness audits to ensure all cases are reported in addition to AHCA and Mortality and FAPTP as well as complete tx.
- Too many cases are being missed from pathology.
- Too much hospital-based treatment is not reported.

Complete Casefinding

- Pathology Reports – up to 10% of cases missed by HIM
- Other Lab Reports – bone marrow, autopsy, addenda, etc.
- In-Patient Discharge Diagnosis Index
- Out-Patient Services Diagnosis/Procedures Index
- Other Ambulatory Patient Services
 - Specialty Clinics – melanoma, head & neck, GI, GYN, etc.
 - Breast Diagnostic/Treatment Center
 - Diagnostic Imaging Center
 - Radiation Oncology Center
 - Medical Oncology Infusion Center
- ICD-9-CM Required Codes
- ICD-10-CM Required Codes

Audits to Assess Completeness

The extent to which all required cases have been reported to FCDS. FCDS file completeness is assessed using:

- ACHA (covers 100% audit of all In-Patient and Out-Patient Visits)
- FAPTP – Florida Association of Pediatric Tumor Programs
- Breast Cancer Early Detection Program Match
- Interstate Data Exchange
- Annual Death Clearance
- Field Casefinding Audits
- E-Path Matching
- Other Linkages
- NDI

NPCR Requires FCDS to be 90% complete 12 months after close of dx year – from all report sources



NPCR Requires FCDS to be 95% complete 24 months after close of dx year – from all report sources

Audits to Assess Completeness

Casefinding Audits

- QC staff will periodically perform on-site review of casefinding procedures and casefinding sources within each facility. (Medical Records, e-path, clinics, other).
- If any case is found to meet the cancer reporting requirements outlined in Section I, the case must be abstracted and reported to FCDS.
- For any case found that does not meet the cancer reporting requirements outlined in Section I, an explanation must be submitted to FCDS detailing the reason it will not be reported.
- Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.
- When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.
- FCDS will add matching and follow-back of e-path records to facility submissions in the future as an annual routine Casefinding Audit and will also be used for Data Validation comparing text-to-code assignments against the original e-path report.

Audits to Assess Completeness

AHCA Clearance and Casefinding Audit

- AHCA is the Agency for Health Care Administration with a primary function of tracking ALL patient encounters (diagnosis, treatment, billing, etc.) for nearly all healthcare facilities in the state of Florida
- ANNUAL Match the FCDS Master File to the Florida AHCA files for both inpatient and outpatient/ambulatory patient encounters. All Facilities.
- FCDS provides each reporting facility with a list of Unmatched AHCA Cases (cases that appear in the AHCA files but have no matching record in the FCDS Master File) and available in FCDS IDEA on the FCDS website.
- Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.
- When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.

Audits to Assess Completeness

Death Clearance and Casefinding Audit

- Many registrars do not recognize Annual Death Clearance as a casefinding audit, but it is. The Florida Bureau of Vital Statistics tracks every birth and death in the state of Florida and has for many years.
- FCDS Conducts an ANNUAL matching of the entire FCDS Master File (3.5 million records) to the annual Vital Statistics Mortality File
- Any “cancer-related” Florida deaths without a matched record in the FCDS Master File are followed back to the hospital or physician authorizing the VS report to determine why the facility/physician did not submit the case.
- Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.
- When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.

Audits to Assess Completeness

FAPTP Clearance and Casefinding Audit

- Many registrars do not recognize this as an audit, but it is. The Florida Association of Pediatric Tumor Programs (FAPTP) captures data on pediatric tumors diagnosed and/or treated within their consortium of hospitals and cancer programs.
- FCDS Conducts an ANNUAL matching of the entire FCDS Masterfile (3.5 million records) to the annual FAPTP File
- Any records found not to match the FCDS Masterfile but having been seen in the facility are followed back to determine why they did not send the case.
- Facilities must explain why they did not report the case – or must immediately abstract and submit the case to FCDS as a “late report”.
- When missed cases are abstracted and submitted, they are classified as a “missed case” found as a result of the audit and counted as a “late report”.

Audits to Assess Timeliness

Timeliness is determined by measuring how long it takes from the time a patient walks through the door of your facility for a diagnosis to be made, treatment plan to be created and initiated, the case is abstracted, the case is uploaded to FCDS without error and more.

- **Standard Set by NAACCR, CDC/NPCR, ACoS/CoC, FCDS:**
 - 95% cases submitted within 6 months from date of service.
 - 100% of cases must be reported by June 30th.
- FCDS Annual June 30th Deadline
- FCDS Quarterly Status Reports
- **Once-A-Year Submissions DO NOT Meet Reporting Requirements**
 - Monthly Reporting is preferred so you stay current
 - Quarterly Reporting for Facilities with >500 cases/year

2014 Change to CoC Standard 5.2

- CoC Standard 5.2 was the 6-month Abstracting Requirement
- **2014 Standard 5.2 was Changed to RQRS Reporting AND On-Time Completed Case Reporting to NCDB in January**
- **NO CHANGE IN FCDS ANNUAL JUNE 30 DEADLINE**
- **NO CHANGE IN FCDS 6-MONTH REPORTING**
- **SUBMIT COMPLETED CASE TO FCDS**
- FCDS not yet set up to receive Update/Modify Records

Audits to Assess Accuracy/Data Quality

The extent to which the data submitted has been correctly and consistently coded and reflects the clinical, diagnostic, descriptive, decisions for treatment planning, or other information contained in the medical record.

- FCDS Abstractor Code Required for Each Abstractor
- FCDS Abstractor Code Annual Renewal
- Policy for Data Submission
- Standard FCDS EDITS Metafile
- Text Documentation Requirements
- Case Corrections / Forces (Edit Override)
- QC Visual Editing – A 3-step Process
- Audits for Completeness
- Audits for Accuracy
- External Audits
- Data Use



Audits to Assess Accuracy/Data Quality

FCDS Validation/Re-abstracting Audits

- The FCDS Quality Control staff and/or outside contract agents working on behalf of FCDS perform on-site or remote access source record review of abstracting and coding by re-abstracting cases from original source paper or electronic medical records for cases previously submitted to FCDS.
- Re-abstracting/Validation Audits assess the consistency in interpretation, instruction and use of standard data definitions, coding rules and guidelines, reference resources, and policies and procedures; and serve to identify areas that may require further education and training
- Reconciliation of Re-abstracting Audit Inconsistencies between original data and audited data is an Important Component: Key data items are evaluated and any discrepancy noted between the auditor's findings and the original abstract findings are returned to the facility for reconciliation.
- **2014 – Intensive Visual Editing Audit and E-Path Data Validation**

External Audits

CDC NPCR Audits (Casefinding/Re-Abstracting/Consolidation)





- The CDC NPCR staff and/or outside contract agents working on behalf of NPCR perform on-site and/or remote review of FCDS Policy and Procedures Manuals, routine operations, standard FCDS EDITS, QC Review, Audits, and Record Consolidation operations and outcomes.
- The CDC NPCR staff and/or outside contract agents working on behalf of NPCR perform on-site and/or remote audits of sources records as well as consolidated FCDS Master File records by reviewing paper and/or electronic medical records, FCDS Master File records, and other available source records on cases previously submitted to FCDS.
- Reconciliation of differences between original data and audited data is an important component: Key data items are evaluated and any discrepancy noted between the auditor's findings and the original abstract findings or consolidation findings are returned to FCDS for reconciliation.

FCDS Data Quality Reports


- FCDS Upload EDIT Discrepancy Journal
- FCDS Quarterly Status Report
- FCDS Data Quality Indicator Report
- FCDS Re-Abstracting Study Report
- NPCR Data Quality Indicator Reports
- NAACCR Certification



Discrepancy Analysis Detail For Batch

		Discrepancy Analysis Detail for Batch		10/31/2012 8:38:20 AM
				Page: 1 of 1
Note: Warnings are not counted as failed edits				
				
2,085 Abstracts		2,038 Passed		47 Failed
2.25% Failure		(119 Total Edits Failed)
# Failures	Percentage	Edit #	Description	
4	3.36%	187	Invalid characters in City at Diagnosis	
4	3.36%	249	Invalid Characters exist in City Current	
33	27.73%	450	The zip code, county, and/or city name spelling combination is not valid according to the United States Postal Service (USPS).	
1	0.84%	467	The format of the Address Current is not a valid USPS address	
1	0.84%	468	The format of the Address at DX is not a valid USPS address	
2	1.68%	874	Addr at DX--Postal code is invalid for FL	
2	1.68%	882	Addr Current--Postal code is invalid for FL	
8	6.72%	883	Addr Current--Postal code must not = 99999	
12	10.08%	887	Addr at DX--City is not a valid FL city name	
2	1.68%	894	If Addr Current--State not = XX, YY, ZZ, AA, AP, AE or Canada, Addr Current--City cannot = UNKNOWN	
12	10.08%	895	Addr Current--City is not a valid FL city name	
1	0.84%	897	If Addr Current--State = FL, County--Current cannot = 999	
4	3.36%	900	If Addr Current--State not = XX, YY, AA, AP, AE or Canada, Addr Current--No/Street cannot = UNKNOWN	
33	27.73%	901	The Addr Current--City, County--Current, and/or Addr Current--Postal Code combination is not valid according to the United States Postal Service (USPS).	

FCDS Edit Check Discrepancy Journal

		Discrepancy Journal		11/15/2012 3:11:24 PM	
				Page: 6 of 9	
Emor:377	Force:Y	Patient has multiple primaries and Dx Confirmation is not equal to 1, 2, 4 or 5 on all Sequences			
<i>Discrepant Data:</i> Inter-Record Edit (PCDS)					
Dx Confirmation for SeqNumber within Pending NOT equal TO 1, 2, 4 OR 5.					
Emor:32	Force:Y	Patient has multiple primaries and Dx Confirmation is not equal to 1, 2, 4 or 5 on all Sequences			
<i>Discrepant Data:</i> Edit: Diagnostic Confir., Seq Num--Hosp (FCDS S)					
E:0032: For Sequence Number--Hospital = 02, Diagnostic Confirmation should not be 7					
Primary Site (540) [C349] Diagnostic Confirmation (562) [7] Sequence Number--Hospital (740) [02] Vendor Name (1936) [MTRIQ2.40]					
Emor:92	Force:N	Sequence 02 being processed without a Sequence 01 in pending file or 00 or 01 in master file			
<i>Discrepant Data:</i> Inter-Record Edit (PCDS)					
Emor:357	Force:Y	Histologic Type ICDO3/Behavior Code ICDO-3 not valid with Primary Site			
<i>Discrepant Data:</i> Edit: Primary Site, Morphology-Type, Beh ICDO3 (SEER IP25)					
E:0357: Histologic Type ICD-0-3 (8507)/Behavior Code ICD-0-3 (3) not valid with Primary Site (C508)					
Primary Site (540) [C508] Histologic Type ICD-0-3 (550) [8507] Behavior Code ICD-0-3 (554) [3] Over-ride Site/Type (1900) [<BLANK>]					
Emor:245	Force:Y	Sequence Greater than Zero with II-Defined Primary Site (C76.* or C80.9) or II-Defined Lymphoma or II-Defined Leukemia			
<i>Discrepant Data:</i> Edit: Seq Num--Hosp, Primary Site, Morph ICDO3 (COC)					
E:0245: Site=C809 & Hist=S140 & Seq Num (02) is greater than 00 - please review					
Sequence Number--Hospital (740) [02] Primary Site (540) [C809] Histologic Type ICD-0-3 (550) [8440] Over-ride HospSeq/Type (1894) [<BLANK>]					
Emor:161	Force:Y	Breast,Prostate - Radiation Rx Date must be less than 365 days after Diagnosis Date			
<i>Discrepant Data:</i> Edit: RX Date--Rad, Primary Site, Date DX+365 (PCDS)					
E:0161: If Site=C509, RX Date--Radiation [Y:2008 M:12 D:02] must be less than 365 days after Date of Diagnosis [Y:2007 M:10 D:29]					
Primary Site (540) [C509] Date of Diagnosis (530) [Y:2007 M:10 D:29] RX Date--Radiation (1486) [Y:2008 M:12 D:02]					
Emor:163	Force:Y	Breast,Prostate - Hormone Rx Date must be less than 365 days after Diagnosis Date			

FCDS Quarterly Status Report

Date

Florida Cancer Data System Quarterly Cancer Case Reporting Status Report

This Quarterly Cancer Case Reporting Status Report is divided in two sections: a Quarterly Activity Summary and an Annual Case Submission Summary. This report is used as a preliminary indication of the completeness, timeliness, and quality of your data.

Quarterly Activity Summary

The Quarterly Activity Summary reflects the file activity and the cases submitted by your facility for the time period specified above.

New Data Submitted:

Total number of cases electronically submitted for this quarter

Total number of good cases: *(cases requiring no changes)*

Total number of forced cases: *(exceptional cases requiring overrides of standard data edits following validation of the data submitted)*

File Activity:

Total number of deleted cases: *(cases deleted due to duplicate record submission; cases that do not meet the FCDS reporting requirements; cases diagnosed prior to the FCDS 1981 reference date)*

Total number of cases in the pending file: *(cases that failed one or more standard data edits during this and any previous quarters and remain in the pending file awaiting data validation)*

Annual Case Submission Summary

The Annual Case Summary reflects all cases submitted by your facility for the past four years. The fifth year displayed is the current reporting year. A two-year average (excluding current year data) is the base from which the Expected Completeness Percentage is calculated.

Admission Year/Case Count	Average # Cases Reported =	
2005		
2004		<u>% Complete for</u>
2003		<u>Reporting Year</u>
2002	Actual	Expected
2001		

Please review this report in detail. If you have any questions or would like additional information please you're your Field Coordinator at (305) 243-4600. Thank you for your cooperation in providing timely and quality data to the FCDS.

FCDS Data Quality Indicator Report

Florida Cancer Data System - Facility Data Quality Indicator Report (DQIR) for 2010

Analytic cases¹ (extracted 3/13/2015)

1647 CLEVELAND CLINIC HOSPITAL

Data Quality Indicator/Admission Year
Demographics:

Total Analytic Cases

Sex Unknown (9)

Race not U.S., NOS (88)

Race Unknown (99)

Ethnicity Unknown (9)

Birth Year Unknown

Birth Month Unknown

Birth Day Unknown

Birthplace US NOS/Unknown (88,999)

Primary Payer Unknown (99)

Marital Status Unknown (9)

Missing/Impossible SSN²

Ungeocoded/No Certainty (9)²

PO Boxes (Certainty 5)²

Tumor Characteristics

Diagnostic Confirmation

Not Microscopically Confirmed (5-8)

DX Method Unknown (9)

Topography

Other/11-Defined Sites (756)

Unknown Primary Site (809)

Morphology Non-specific (8000-8005)

Grade Unknown (excludes C80.9)

Period/Summary Stage-2000 Unknown (9)

Code	2010		2009		2008		2007		2006	
	Facility %	Florida Facilities %	Facility %	Florida Facilities %	Facility %	Florida Facilities %	Facility %	Florida Facilities %	Facility %	Florida Facilities %
	999	110,777	998	114,920	801	114,017	759	111,937	697	109,096
0 %	0.000	0.002	0.000	0.000	0.250	0.046	0.000	0.046	0.000	0.061
< 1%	1.707	1.088	0.999	0.999	4.120	0.837	5.413	0.718	2.143	0.701
< 1%	0.301	0.839	1.492	1.396	0.125	1.129	0.661	1.244	0.824	1.291
< 1%	0.703	0.958	1.509	0.797	3.346	0.967	2.116	0.820	2.471	0.699
0 %	0.000	0.000	0.000	0.000	0.000	0.002	0.000	0.001	0.000	0.003
0 %	0.000	0.000	0.000	0.000	0.000	0.002	0.000	0.001	0.000	0.003
0 %	0.000	0.000	0.000	0.000	0.000	0.002	0.000	0.001	0.000	0.003
92.068	75.090	88.273	73.072	92.094	79.324	94.677	71.894	89.611	71.171	
0 %	3.012	1.988	11.820	1.184	48.067	1.441	10.714	1.156	10.768	1.344
< 2%	5.522	2.484	3.943	2.837	5.499	1.979	1.823	1.789	2.471	2.206
< 1%	12.442	1.501	7.986	1.840	8.093	1.959	7.296	1.725	2.011	1.993
< 2%	0.115	0.181	0.000	0.129	0.000	0.120	0.000	0.141	0.000	0.112
0%	1.382	2.168	1.263	2.544	1.372	2.168	1.481	2.465	2.011	2.931
< 2%	1.219	0.901	3.398	0.991	1.748	0.332	1.381	0.339	1.647	0.344
0%	0.001	0.097	0.213	0.046	0.129	0.002	0.132	0.099	0.165	0.099
< 1%	0.000	0.002	0.107	0.037	0.000	0.046	0.000	0.034	0.000	0.034
< 1%	1.104	1.964	1.173	1.994	0.375	1.902	0.794	1.961	0.988	2.148
< 2%	1.365	1.996	1.383	2.194	0.390	3.011	0.794	2.191	1.153	2.138
< 2%	29.618	34.672	32.834	34.355	27.940	34.964	34.399	34.937	28.259	34.184
< 2%	1.198	6.227	1.343	6.822	1.347	7.138	3.779	7.571	3.460	8.194

* 99999999, 123456789, 111111111, 123123123, 33333333, 44444444, 55555555, 66666666, 77777777, 88888888, 00000000, 77500000, 987654321

¹ Analytic according to FCDS (date of case: 0 - 12 or 34 - 42)

² Percentages based on analytic cases of Florida residents at time of DX only.

FCDS Re-Abstracting Audit Report

- Major Difference
 - Affects incidence counts
 - Affects research
 - Examples: diagnosis year, primary site, sex
- Minor Difference
 - Does not affect incidence counts
 - Examples: quadrant of breast, type of resection
- Unknown-to-Known
 - Valid data found but initially coded as unknown
 - Difference depends on data item

FCDS Re-Abstracting Audit Report


FCDS		Reabstract Summary Report				7/13/2012 9:30:30 AM	
		For Audit Year:				Page: 6 of 16	
		Facilities:				A	
Facility Completed: 0	FCDS Completed: 15						
Demographic	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Admit Date	1	6.67			1	6.67	
Patient First Name							
Middle Initial	1	6.67			1	6.67	
Date Of Birth							
Birthplace Geocode	1	6.67			1	6.67	
SSN							
Race	2	13.33			2	13.33	
Race2							
Race3							
Race4							
Race5							
Ethnicity			2	13.33	2	13.33	
Marital Status	2	13.33			2	13.33	
Address DX	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Dx Address	2	13.33			2	13.33	
Add Dx City							
Address	2	13.33			2	13.33	
City							
Dx Primary Payor	1	6.67			1	6.67	
Dx Method	1	6.67			1	6.67	
Case Class	7	46.67			7	46.67	
Case Dx	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Dx Date							
Primary Site			1	6.67	1	6.67	
Morphology Icd03							
Grade							
Laterality			1	6.67	1	6.67	
Treatment	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Surgical Treatment	2	13.33			2	13.33	
Scope Surg							
Reason No Surgery	2	13.33			2	13.33	
Surgery Date							
Radiation Treatment							
Radiation Date							
Rad Rx Modality							
Chemo Treatment							
Chemo Date	1	6.67			1	6.67	
Hormone Treatment							
Hormone Date	1	6.67			1	6.67	
Brm Therapy							
Brm Date							
Surg Rad Seq	2	13.33			2	13.33	
Systemic Surg Seq	1	6.67			1	6.67	

FCDS		Reabstract Summary Report				7/13/2012 9:30:30 AM	
		For Audit Year:				Page: 11 of 16	
		Facilities:				B	
Facility Completed: 0	FCDS Completed: 15						
Demographic	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Admit Date	4	26.67			4	26.67	
Report Source							
Patient Last Name			1	6.67	1	6.67	
Middle Initial	1	6.67			1	6.67	
Marital Status	1	6.67			1	6.67	
Address DX	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Dx Address	10	66.67			10	66.67	
Add Dx City	1	6.67			1	6.67	
Dx Zip Code			1	6.67	1	6.67	
Address	8	53.33			8	53.33	
City	1	6.67			1	6.67	
Zip Code							
Dx Primary Payor	8	53.33			8	53.33	
Dx Method							
Case Class	3	20.00			3	20.00	
Case Dx	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Dx Date			5	33.33	5	33.33	
Primary Site			3	20.00	3	20.00	
Morphology Icd03			1	6.67	1	6.67	
Grade	1	6.67			1	6.67	
Treatment	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Surgical Treatment	4	26.67			4	26.67	
Scope Surg	2	13.33			2	13.33	
Reason No Surgery							
Surgery Date							
Radiation Treatment							
Radiation Date							
Rad Rx Modality							
Chemo Treatment	2	13.33			2	13.33	
Chemo Date	2	13.33			2	13.33	
Hormone Treatment							
Hormone Date							
Brm Therapy							
Brm Date							
Surg Rad Seq	2	13.33			2	13.33	
Systemic Surg Seq							
Follow-Up	Minor Discrepancy		Major Discrepancy		Total Discrepancies		
	Count (n=15)	Pct	Count (n=15)	Pct	Count (n=15)	Pct	
Vital Status	1	6.67			1	6.67	
Cancer Status							
Total Master File Records:	15						

NPCR Data Quality Reports



2013 Data Evaluation Reports National Program of Cancer Registries Cancer Surveillance System (National Data Quality)



Florida



Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People

NPCR Data Quality Reports




**2013 - Standard Status Report (SSR1)
National Program of Cancer Registries
Cancer Surveillance System
(National Data Quality)**

Florida



**Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People**

NPCR Data Quality Reports



Florida



Report on Quality, Completeness and Timeliness of Data*

NPCR Standards Grouping	Diagnosis Year**	Percent Completeness Adjusted for Duplicates*	Unresolved Duplicate Rates (per 1,000)	Percent Death Certificate Only	Percent Missing or Unknown Core Data Elements				Percent Passing Core Single and Inter-field Edits	1995-2010 Percent Passing Core Inter-record Edits***
					Age	Sex	Race	County		
National Data Quality	2010	95.14	0.00	1.93	0.00	0.03	0.78	0.00	100.00	100.00
	2009	98.66	0.00	1.97	0.00	0.03	0.93	0.00	100.00	
	2008	102.04	0.00	2.63	0.00	0.07	0.79	0.00	100.00	
	2007	100.02	0.00	2.34	0.00	0.06	0.98	0.00	100.00	
	2006	99.34	0.00	2.47	0.00	0.04	0.95	0.00	100.00	
STANDARD										
National Data Quality Standard		95.00	<=1	<=3	<=2	<=2	<=3	<=2	99.00	99.00
USCS Publication Standard		90.00	N/A	<=5	<=3	<=3	<=5	N/A	97.00	97.00
Measurement Error****		-1.0	-0.4	-0.4	-0.4	-0.4	-0.4	-0.4	N/A	N/A

NPCR Data Quality Reports

2010 Dx Year

Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records

Total Incident Cases	102168	Adjusted Total Incident Cases	102168
Race Proportional Completeness, Adjusted for Reference Mortality	95.14	Expected Incident Cases	107383
%Unresolved Duplicates*	0.00	Final Completeness Estimates, Adjusted for Reference Mortality and Duplicate Records	95.14

* 0.00 indicates all duplicates are resolved.

2009 Dx Year

Final Completeness Estimates Adjusted for Reference Mortality and Duplicate Records

Total Incident Cases	106772	Adjusted Total Incident Cases	106772
Race Proportional Completeness, Adjusted for Reference Mortality	98.66	Expected Incident Cases	108217
%Unresolved Duplicates*	0.00	Final Completeness Estimates, Adjusted for Reference Mortality and Duplicate Records	98.66

* 0.00 indicates all duplicates are resolved.

NPCR Data Quality Reports



**2013 - Submission Summary Report (SSR2)
National Program of Cancer Registries
Cancer Surveillance System
(National Data Quality)**

Florida



**Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People**

NPCR Data Quality Reports



Florida



Table 1: Submission Summary

Diagnosis Year	Record Status					
	Records Received	Non-reportable Records	Reportable Records	Invasive Records*	In Situ Records	Benign Brain Records
2010	112037	0	112037	102166	6540	3331
2009	117564	0	117564	106772	7249	3543
2008	119027	0	119027	108297	7345	3385
2007	116930	0	116930	106427	7313	3190
2006	114304	0	114304	104404	6606	3294
<= 2005 **	1147891	0	1147891	1085770	55807	6314
Prior to NPCR Reference Year	0	0	0	0	0	
Total	1727753	0	1727753	1613836	90860	23057

* Invasive records include In situ bladder.

** Includes all submitted records from the NPCR reference year through 2005.

NPCR Data Quality Reports



Florida

Table 3 : Percentage of Over-Ride Flagged Fields – Grouped by Edit Name and Diagnosis Year

OVER-RIDE FLAG NAME														Percentage of Records with Over-Ride flags*
Age/Site/Morph [1880]	SeqNo/DxConf [2000]	Site/Lat/SeqNo [2010]	Site/Type [2030]	Histology [2040]	Report Source [2060]	Ill-define Site [2080]	Leuk, Lymphoma [2070]	Site/Behavior [2071]	Site/Lat/Morph [2074]					
ASSOCIATED EDIT NAME														
Diagnosis Year	Age, Primary Site, Morphology (NAACCR IF15)	Diagnostic Confirm, Seq Num-Central (\$EER IF23)	Site/Histology/Laterality/Sequence Number (IR08)	Primary Site, Morphology-Type Check (\$EER IF26)	1 = Morphology-Type&Behavior (\$EER MORPH)	2 = Diagnostic Confirmation, Behavior Code (\$EER IF31)	3 = Both 1 and 2 Apply	Type of Report Sroe(DC),Seq Num-Central (\$EER IF04)	Seq Num-Central, Primary Site, Morph (\$EER IF22)	Diagnostic Confirmation, Histology Type (\$EER IF48)	Primary Site, Behavior Code (\$EER IF38)	Laterality, Primary Site, Morphology (\$EER IF42)		
2010	0.12	1.26	0.27	0.72	0.76	0.00	0.00	0.03	0.83	0.00	0.01	0.00	4.00	
2009	0.09	1.02	0.22	0.69	0.69	0.00	0.00	0.02	0.85	0.00	0.00	0.00	3.59	
2008	0.11	0.94	0.26	0.65	0.57	0.00	0.00	0.04	0.75	0.00	0.00	0.00	3.32	
2007	0.11	0.89	0.30	0.67	0.19	0.00	0.00	0.03	0.78	0.00	0.00	0.00	2.97	
2006	0.10	0.86	0.25	0.92	0.12	0.00	0.00	0.05	0.76	0.01	0.00	0.00	3.07	
SEER OVER-RIDE FLAG QUALITY MEASURES**														
	0.16	0.93	0.38	1.32	0.23	0.02	0.02	0.12	0.40	0.04	0.06	0.07		

NPCR Data Quality Reports



**2013 - Data Quality Indicator Report (DQI)
National Program of Cancer Registries
Cancer Surveillance System
(National Data Quality)**

Florida



**Department of Health and Human Services
Centers for Disease Control and Prevention
Safer • Healthier • People**

NPCR Data Quality Reports

Table 1: Core Cancer Surveillance Data

Data Quality Indicator* \ Diagnosis Year	2006		2007		2008		2009		2010		NPCR Median(Range)	SEER Median(Range)**
	FL	NPCR Median(Range)	FL	NPCR Median(Range)	FL	NPCR Median(Range)	FL	NPCR Median(Range)	FL	NPCR Median(Range)	2006-2010	2005-2009
Demographics												
County at Diagnosis [90]												
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Unknown (999)	0.00	0.01(0.00 - 0.56)	0.00	0.02(0.00 - 1.05)	0.00	0.02(0.00 - 0.48)	0.00	0.04(0.00 - 0.77)	0.00	0.02(0.00 - 1.06)	0.02(0.00 - 1.06)	0.00(0.00 - 1.19)
County Recode (000)	0.00	0.00(0.00 - 23.81)	0.00	0.00(0.00 - 22.83)	0.00	0.00(0.00 - 23.16)	0.00	0.00(0.00 - 23.93)	0.00	0.00(0.00 - 22.44)	0.00(0.00 - 23.93)	0.00(0.00 - 0.00)
Spanish/Hispanic Origin [190]												
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Unknown (9)	0.54	2.86(0.00 - 24.64)	0.62	2.63(0.00 - 22.97)	0.74	2.43(0.00 - 30.81)	0.58	3.07(0.00 - 21.34)	0.76	2.50(0.00 - 24.34)	2.77(0.00 - 30.81)	1.24(0.00 - 8.61)
NHIA Derived Hisp Origin [191]												
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Invalid (9)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Birthdate [240]												
Year (<1950 or >2010, blank)	0.00	0.00(0.00 - 0.04)	0.00	0.00(0.00 - 0.02)	0.00	0.00(0.00 - 0.04)	0.00	0.00(0.00 - 0.05)	0.00	0.00(0.00 - 0.07)	0.00(0.00 - 0.07)	0.00(0.00 - 0.03)
Birthplace [250]												
Not in US but NOS (998)	0.05	0.03(0.00 - 1.05)	0.05	0.03(0.00 - 1.82)	0.06	0.04(0.00 - 2.64)	0.11	0.03(0.00 - 2.34)	0.03	0.04(0.00 - 2.18)	0.03(0.00 - 2.64)	0.08(0.00 - 4.06)
Unknown (999, Blank)	57.52	52.91(7.62 - 83.07)	58.11	53.97(7.52 - 87.71)	58.61	58.63(9.30 - 86.08)	58.75	59.93(9.38 - 85.73)	61.39	64.69(11.45 - 88.44)	58.77(7.52 - 88.44)	47.69(3.91 - 72.21)
Tumor Characteristics												
Sequence Number-Central [380]												
Two or more (01 - 35)	27.97	22.12(15.57 - 27.97)	27.78	21.90(15.64 - 27.78)	27.30	21.45(15.18 - 27.30)	26.71	20.95(14.31 - 26.71)	25.81	20.76(13.88 - 25.81)	21.54(13.88 - 27.97)	21.51(15.13 - 27.77)
Unspecified (99)	0.00	0.00(0.00 - 1.27)	0.00	0.00(0.00 - 0.01)	0.00	0.00(0.00 - 0.01)	0.00	0.00(0.00 - 0.01)	0.00	0.00(0.00 - 0.02)	0.00(0.00 - 1.27)	0.00(0.00 - 0.07)
Date of Diagnosis [390]												
Month (blank)	0.04	0.30(0.00 - 2.00)	0.05	0.27(0.00 - 2.47)	0.05	0.28(0.00 - 2.88)	0.03	0.21(0.00 - 2.62)	0.04	0.24(0.00 - 2.54)	0.26(0.00 - 2.88)	0.00(0.00 - 0.00)
Topography [400]												
Other/II Defined Sites (C76.0 - C76.8)	0.03	0.10(0.03 - 0.20)	0.05	0.10(0.04 - 0.28)	0.07	0.11(0.03 - 0.25)	0.06	0.10(0.04 - 0.19)	0.06	0.11(0.02 - 0.21)	0.10(0.02 - 0.28)	0.08(0.00 - 0.56)
Unknown Primary Site (C80.9)	2.50	2.07(1.16 - 2.89)	2.48	1.93(1.19 - 2.80)	2.29	1.94(1.10 - 2.90)	2.42	2.00(1.19 - 2.94)	2.46	1.94(1.13 - 2.77)	1.97(1.10 - 2.94)	1.66(0.87 - 2.52)
Morphology [420]												
Non-specific Neoplasms (8000 - 8005)	5.07	3.59(1.67 - 7.24)	4.99	3.51(1.55 - 7.51)	4.95	3.52(1.75 - 7.16)	4.53	3.50(1.83 - 7.09)	4.41	3.41(1.73 - 6.87)	3.51(1.55 - 7.51)	2.48(1.46 - 6.72)
Diagnostic Confirmation [490] excludes DCO												
Not Microscopically Confirmed (5, 6, 7, 8)	3.15	3.83(2.04 - 6.28)	3.08	3.82(2.17 - 6.35)	3.02	3.84(2.04 - 6.44)	3.20	3.98(1.85 - 5.52)	3.47	3.66(2.08 - 5.96)	3.82(1.85 - 6.44)	3.48(2.36 - 7.00)
Unknown (9) and Blank	0.37	1.00(0.06 - 3.99)	0.53	0.85(0.03 - 3.57)	0.39	0.98(0.03 - 3.98)	0.41	0.96(0.05 - 4.03)	0.43	0.82(0.01 - 5.01)	0.92(0.01 - 5.01)	0.50(0.00 - 2.31)
Tumor Miscellaneous												
Grade [440] (5, blank) excludes DCO, C80.9	33.31	32.88(27.38 - 37.15)	33.35	32.99(27.53 - 36.47)	33.39	33.39(28.35 - 36.88)	33.32	33.32(27.89 - 39.05)	33.50	31.52(26.17 - 40.73)	32.94(26.17 - 40.73)	33.81(27.23 - 38.75)
Laterality [410] paired organs only												
Only 1 side and side NOS (3)	0.17	0.13(0.00 - 1.33)	0.16	0.13(0.00 - 1.18)	0.18	0.11(0.00 - 0.64)	0.20	0.09(0.02 - 1.10)	0.15	0.11(0.01 - 1.28)	0.11(0.00 - 1.33)	0.14(0.00 - 1.77)
Unknown (9, blank)	2.58	2.52(1.18 - 4.87)	2.41	2.33(0.91 - 5.49)	2.51	2.32(1.36 - 4.45)	2.16	2.31(1.11 - 6.00)	2.09	2.25(0.95 - 5.68)	2.32(0.91 - 6.00)	1.68(0.42 - 3.25)

NPCR Data Quality Reports

Table 1: Core Cancer Surveillance Data

Data Quality Indicator* \ Diagnosis Year	2006		2007		2008		2009		2010		NPCR Median(Range)	SEER Median(Range)**
	FL	NPCR Median(Range)	FL	NPCR Median(Range)	FL	NPCR Median(Range)	FL	NPCR Median(Range)	FL	NPCR Median(Range)	2006-2010	2005-2009
Blank	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 100.00)	0.00(0.00 - 0.00)
Unknown (999)	12.97	9.67(0.00 - 17.42)	10.32	8.12(0.00 - 16.13)	9.37	7.29(0.00 - 15.74)	8.93	7.02(0.00 - 14.23)	7.53	6.04(3.85 - 14.08)	7.56(0.00 - 17.42)	6.40(3.46 - 11.98)
CS Mets at DX [2850]												
Blank	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 100.00)	0.00(0.00 - 0.00)
Unknown (99)	7.87	6.34(0.00 - 20.58)	6.49	5.90(0.00 - 16.00)	5.77	5.51(0.00 - 15.99)	5.66	5.09(0.00 - 15.76)	3.95	3.90(2.23 - 16.86)	5.28(0.00 - 20.58)	3.60(1.78 - 10.22)
Derived Summary Stage 2000 [3020]												
Unknown/Unstaged (9)	8.09	5.04(2.62 - 13.20)	7.37	4.83(2.54 - 9.79)	6.89	4.26(2.18 - 10.86)	6.41	4.36(2.53 - 10.65)	5.92	4.06(1.96 - 11.33)	4.47(1.96 - 13.20)	2.84(1.36 - 7.44)
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
First Course Treatment												
RX Summ Surg Prim Site [1290]												
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Surgery, NOG (90)	0.94	0.48(0.11 - 3.69)	0.79	0.40(0.08 - 3.41)	0.79	0.39(0.13 - 3.65)	0.74	0.42(0.07 - 3.94)	0.87	0.40(0.13 - 3.42)	0.41(0.07 - 3.94)	0.20(0.00 - 2.06)
Unknown (99)	3.45	3.54(0.84 - 12.86)	2.96	3.23(0.69 - 13.09)	3.14	3.17(0.44 - 12.94)	2.34	2.50(0.52 - 13.36)	2.07	2.78(0.63 - 10.86)	3.14(0.44 - 13.36)	1.28(0.44 - 5.93)
Blank and Unknown Combined	3.45	3.54(0.84 - 12.86)	2.96	3.23(0.69 - 13.09)	3.14	3.17(0.44 - 12.94)	2.34	2.50(0.52 - 13.36)	2.07	2.78(0.63 - 10.86)	3.14(0.44 - 13.36)	1.28(0.44 - 5.93)
RX Summ Scope Reg LN Sur [1292]												
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Unknown (9)	16.87	16.75(12.84 - 24.01)	16.50	16.26(12.62 - 24.21)	16.43	16.04(12.22 - 25.14)	15.83	16.13(11.59 - 27.45)	15.84	16.15(12.85 - 27.41)	16.16(11.59 - 27.45)	28.57(23.79 - 32.53)
Blank and Unknown Combined	16.87	16.75(12.84 - 24.01)	16.50	16.26(12.62 - 24.21)	16.43	16.04(12.22 - 25.14)	15.83	16.13(11.59 - 27.45)	15.84	16.15(12.85 - 27.41)	16.16(11.59 - 27.45)	28.57(23.79 - 32.53)
RX Summ Surg Oth Reg/Dis [1284]												
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Unknown (9)	11.24	3.82(0.95 - 14.66)	10.94	4.11(0.88 - 14.43)	11.28	4.02(0.76 - 13.81)	10.71	3.86(1.04 - 16.19)	10.76	3.67(1.03 - 14.57)	3.83(0.76 - 16.19)	1.32(0.52 - 9.89)
Blank and Unknown Combined	11.24	3.82(0.95 - 14.66)	10.94	4.11(0.88 - 14.43)	11.28	4.02(0.76 - 13.81)	10.71	3.86(1.04 - 16.19)	10.76	3.67(1.03 - 14.57)	3.83(0.76 - 16.19)	1.32(0.52 - 9.89)
Reason for No Surgery [1340]												
Blank	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)	0.00(0.00 - 0.00)
Unknown (9)	3.85	7.18(0.94 - 20.67)	3.35	7.10(0.93 - 18.94)	3.58	6.68(0.97 - 19.05)	2.63	6.23(1.11 - 21.65)	2.40	5.75(0.99 - 23.02)	6.65(0.93 - 23.02)	1.42(0.48 - 5.76)
Blank and Unknown Combined	3.85	7.18(0.94 - 20.67)	3.35	7.10(0.93 - 18.94)	3.58	6.68(0.97 - 19.05)	2.63	6.23(1.11 - 21.65)	2.40	5.75(0.99 - 23.02)	6.65(0.93 - 23.02)	1.42(0.48 - 5.76)
RX Summ Radiation [1380]												
Blank	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00	0.00(0.00 - 100.00)	0.00(0.00 - 100.00)	0.00(0.00 - 0.00)
Unknown (9)	3.44	2.69(0.00 - 17.07)	3.17	2.62(0.00 - 14.25)	3.39	2.75(0.00 - 16.49)	2.64	2.60(0.00 - 15.43)	2.30	2.79(0.00 - 86.55)	2.72(0.00 - 86.55)	1.20(0.24 - 10.65)
Blank and Unknown Combined	3.44	3.31(0.15 - 100.00)	3.17	3.70(0.49 - 100.00)	3.39	3.64(0.60 - 100.00)	2.64	3.39(0.91 - 100.00)	2.30	3.33(0.99 - 100.00)	3.39(0.15 - 100.00)	1.20(0.24 - 10.65)
RX Summ Surg/Rad Seq [1380]												
Blank	0.00	0.00(0.00 - 0.03)	0.00	0.00(0.00 - 0.05)	0.00	0.00(0.00 - 0.05)	0.00	0.00(0.00 - 0.26)	0.00	0.00(0.00 - 0.82)	0.00(0.00 - 0.82)	0.00(0.00 - 0.00)
Unknown (9)	0.24	0.22(0.00 - 6.09)	0.19	0.15(0.00 - 5.99)	0.20	0.19(0.00 - 5.81)	0.27	0.12(0.00 - 6.66)	0.31	0.13(0.00 - 5.45)	0.16(0.00 - 6.66)	0.03(0.00 - 1.26)
Blank and Unknown Combined	0.24	0.22(0.00 - 6.09)	0.19	0.16(0.00 - 5.99)	0.20	0.19(0.00 - 5.81)	0.27	0.13(0.00 - 6.66)	0.31	0.15(0.00 - 5.45)	0.17(0.00 - 6.66)	0.03(0.00 - 1.26)
RX Summ Chemo [1390]												
Blank	0.00	0.00(0.00 - 0.01)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00	0.00(0.00 - 0.00)	0.00(0.00 - 0.01)	N/A
Unknown (99)	5.04	5.69(1.22 - 49.09)	4.33	5.48(0.69 - 39.47)	4.30	5.03(1.07 - 22.13)	2.61	3.33(1.02 - 21.16)	2.37	4.24(1.01 - 14.90)	4.69(0.69 - 49.09)	N/A

NAACCR Registry Certification



Other – Reinforcement

- ✓ Monitor Compliance with Feedback to Registrar and Administration
- ✓ Data Quality and Timeliness Reports to Administration
- ✓ Targeted Education and Training Programs
 - FCDS Annual Conference
 - FCDS Annual Series of Webcasts
 - 5 per year or as needed
 - Recorded and archived
 - FCDS On-Line Abstractor Training Course
 - Published Resources for Registrars
 - Monthly NAACCR Educational Webcast Series at 7 Locations in FL



Other – Incentives and Rewards

- Jean Byers Award including Publication of Name in Register
- Individual Abstractor Recognition Certificates
- Other Recognition – Future of Rewards



FCDS Education and Training

- **New Registrar Recruitment**
- **Instruction:** FCDS/National Coding Rules and Guidelines
- **Instruction:** FCDS/National Policy/Procedures
- **Re-Instruction:** Existing Rules/Procedures – **Correct Problems**
- **Instruction:** Changes To / New Rules/Procedures
- **Continuing Education – Increase Knowledge Base**
- **Retention of Qualified Staff**

FCDS Education and Training

- On-Line Abstracting Course for New Registrars
- FCDS Abstractor Code
- FCDS Annual Conference
- FCDS Annual Webcast Series
- NAACCR Cancer Registry Webinar Series
- NAACCR CTR Exam Prep and Review Webinar Series
- Ad Hoc Webcasts for New Programs/Policy/Procedure/Other
- FCDS Staff In-Services
- FCDS EDITS In-Services
- Personalized Instruction

FCDS Education and Training


NCRA CEU #	Date	Event	Sponsor	CEU Hrs
2013-114	7/25/2013 - 7/26/2013	FCDS Annual Conference, Sunrise, FL	FCDS	8.25
2013-115	8/22/2013	Webcast : "What's New for 2013 and More - Annual Meeting Review"	FCDS	2
2013-116	9/19/2013	Webcast: "Lung Neoplasms-Background/Anatomy/Risk Factors/MPH Rules/CS02.04/SSF/Tx"	FCDS	2
2013-117	10/24/2013	Webcast : "New Developments in FCDS Quality Improvement and Education and Training"	FCDS	2
2013-118	11/21/2013	Webcast: "Breast Neoplasms-Background/Anatomy/Risk Factors/MPH Rules/CS02.04/SSF/Tx"	FCDS	2
2013-119	12/12/2013	Webcast : "Colon/Rectum Neoplasms- Background/ Anatomy/Risk Factors/MPH Rules/CSv02.04/SSF/Tx"	FCDS	2
2013-120	1/17/2014	Webcast : "FCDS Learning Management System – What's New for 2014 and Version 2.0 of FCDS LMS"	FCDS	2
2013-121	2/21/2014	Webcast : "Lymphoid Neoplasms - Background/Anatomy/Risk Factors/MPH Rules/CSv02.04/SSF/Tx"	FCDS	2

FCDS Education and Training

Event	CEU Education Hours
FCDS Annual Meeting	8-10
FCDS Webcasts	10-16
NAACCR Webinars	36
NAACCR CTR Exam Prep	n/a
ANNUAL TOTAL FCDS-Sponsored	60+ hours of education offered FREE each year

Other New Education Portals

<http://www.CancerRegistryEducation.org>



- Live Webinars
- Learning Modules
- Online Courses
- CTR Exam Study Materials
- Online CTR Exam Practice Test
- More to Come

Other New Education Portals

CDC Home



Centers for Disease Control and Prevention

Your Online Source for Credible Health Information

Cyber Cancer Registry

[Reportability Options](#) | [References](#) | [Help](#) | [Log Out](#)

Welcome Steven Peace

Casefinding Module

Comments

Welcome to the Cyber Cancer Registry!

The Cyber Cancer Registry is an interactive tool developed by CDC's National Program of Cancer Registries (NPCR) to prepare people for a career in the cancer registry field. By working through the exercises and quizzes, you will gain practical experience in the functions of a cancer registrar in both hospitals and central registries.

For technical questions about the Cyber Cancer Registry, please contact the [system administrator](mailto:cancerinfo@cdc.gov) (cancerinfo@cdc.gov).

Casefinding Module

Casefinding Practice

Practice the exercises in this module to gain experience in the casefinding functions of a cancer registrar. You may repeat the practice exercises as many times as you like. In general, there are 20 practice exercises displayed at a time with a unique report ID number.

For this module, you may download the

[Screening List of ICD-9-CM Codes for Casefinding](#)

(PDF-22KB) and the

[Reportable Diagnoses](#)

document (PDF-33KB), which includes ambiguous terminology rules. Please use these documents in your decisions for reportability. More information is available from the [References](#) link at the top.

Casefinding Quiz

Take the Casefinding Quiz at any time and receive a certificate upon completion. You may repeat the quiz as many times as you like. However, the quiz must be completed in one session, so please allow enough time to finish.

Other New Education Portals



Surveillance Epidemiology and End Results

providing information on cancer statistics to help reduce the burden of this disease on the U.S. population

<https://educate.fhcrc.org/>

SEER* Educate

Introduction Menu ▾ Training Menu ▾ Reports Menu ▾

Overview Videos

- ▶ Introduction
- ▶ Training
- ▶ Reports

How To Videos

- ▶ Take a Test
- ▶ Code a Case
- ▶ Run a Report

... **Learn by doing**

Medical
Terminology


Computer
Principles

ACoS/CoC
Standards


Real-Life Case Scenarios

Other New Education Portals



Firefox Browser Supported Only
<https://educate.fhcrc.org>



Fred Hutchinson Cancer Research Center
 Cancer Surveillance System
 1100 Fairview Ave. North
 Seattle, WA 98109
 Phone: +1 (206) 667-4709
 Educate@fhcrc.org



SEER*Educate
 Learn by doing

- CTR TRAINING
- REAL CASES
- FREE
- CE ELIGIBLE
- DIGITAL PLATFORM
- EASY ACCESS
- PRACTICAL
- APPLICABLE
- SUSTAINABLE
- COMPREHENSIVE

- *Prepare for CTR exam*
- *Earn CEU credits free*
- *Train on real-life case scenarios*
- *Learning new coding schemes, rules, and guidelines*
 - *295 Practice Cases*
 - *12 Major Site Groups*
 - *60+ Data Items Coded*

Other New Education Portals

<http://eo2.commpartners.com>

You are logged in as:
Steven Peace

Log Out



AMERICAN COLLEGE OF SURGEONS

Cancer Programs Online Education Portal

[Home](#) [All Webinars](#) [CoC](#) [AJCC](#) [NAPBC](#) [CLP](#) [FAQs](#) [System Check](#) [My Account](#)



Cart: empty

Welcome to the Cancer Programs Education Portal of the American College of Surgeons. This site holds a wealth of educational opportunities for individuals involved in cancer care and work with the following organizations: the Commission on Cancer, the National Accreditation Program for Breast Centers, and the American Joint Committee on Cancer.

Need assistance logging in or navigating this site? The videos below will guide you through creating a new user account on the site and how to order and view content.

Other New Education Portals

<http://moodle.med.miami.edu/server/moodle/>

Florida Cancer Data System: Learning Management System

My courses

COURSE 1 - FCDS Online Abstracting Basics Course

FCDS: FCDS LMS

A basic abstracting course designed to provide an understanding and the fundamentals of incidence cancer case abstracting within the state of Florida.

This course **IS NOT** intended to prepare a student to sit for a CTR exam. This basic course is moderately detailed and provides the student with the fundamentals of incidence abstracting and an overview of cancer registration.

The course is comprised of approximately 1,000 Powerpoint Slides with voiceovers. At the end of each section, there is an examination. Each section must be completed in order to move to the next section. At the end of the course, the student will be given a Certificate of Completion that will include the raw score for each of the examinations.

LOGGED IN USER

Steven Peace

speace@med.miami.edu

Last access: Tuesday, 22 October 2013, 12:18 PM

Login: Tuesday, 22 October 2013, 12:18 PM

NAVIGATION

[Home](#)

[My home](#)

[Site pages](#)

[Tags](#)

[My profile](#)

[My courses](#)

SETTINGS

[My profile settings](#)

FCDS Online Abstracting Basics Course

FCDS Abstractor Code Initial Exam

FCDS Abstractor Code Renewal Exam

Other State Abstractor Code Exams

More to Come

FCDS “Future Vision”




How is QC/Education Changing?

- FCDS Goals and Objectives have not changed
- FCDS will continue all reporting requirements.
- FCDS making every attempt to make any changes minimal.
- FCDS making every attempt to make any changes seamless.
- FCDS will continue to plan for upcoming changes
 - TNM, SS2000, physician reporting, and more
- FCDS will continue enforcing deadlines/reporting compliance.
- FCDS will continue to be available for technical Q&A.

How is QC/Education Changing?

- Monitoring Activities will likely be enhanced
- Feedback to Hospitals still being planned
- Some QC Activities will be cut back
 - FCDS will continue all EDITS requirements.
 - FCDS will continue to perform QC Reviews.
 - FCDS will continue to perform completeness audits with F/B.
 - FCDS will continue to perform validation audits and reconciliation.
- Some Education/Training Activities will be cut back
 - FCDS will continue to offer NAACCR Webinars.
 - FCDS will continue to offer NAACCR CTR Prep Series.
 - FCDS will continue to host an Annual Meeting.
 - FCDS will continue to host a Florida Webcast Series.

THE PERFECT DESIGNER WORKSTATION



Hair styling and beard grooming machine



3 in one device, Mouse and Graphics Tablet, game controller pad

Web Safe Color Code Chart



5 Different LED Screen Sizes for responsive testing and multi-tasking

Punching Desktop Mime Figure to represent the client, developer or IE



Typeface Chart

Randomly generated quotes to praise yourself



Web cam with filters and mic with autotone for your video and podcast

Wireless Headphone Dock

Auto Coffee Dispensing Machine



Mini Fridge compartment

Instant PSD to HTML conversion button

Self wash toilet seat with back massage function

Customizable Photoshop Shortcuts Pedals (Alt+Shift+Ctrl+S= Saved for web version, Ctrl+Alt+Z =Undo, e.g)

Mind reader to read clients needs

Ultra slim water proof keyboard with quick dial to your favorite food delivery outlet

Smartphone with auto instant voice language translation for international clients

CURRENT FCDS QC ISSUES



Reportable Cases - Required

Reporting Historical Cancers to FCDS – FCDS DAM

- Although the American College of Surgeons/Commission on Cancer does not require accredited facilities to abstract historical cases, FCDS does require the collection and reporting of certain historical cancers.
- **DEFINITION:** A historical case (Class of Case 33) refers to a primary reportable neoplasm (malignant or benign/borderline brain/CNS tumors).
- Patients diagnosed with any cancer during their lifetime are many times more likely to develop new cancers. It is very important for researchers to know the number and types of any and all cancers each patient has during his/her lifetime in order to effectively research and evaluate cancer incidence.

-

Reportable Cases - Required

Reporting Historical Cancers to FCDS – FCDS DAM

If a patient has at least one primary reportable neoplasm which is active or under treatment, all other primary reportable neoplasms the patient has ever had (active or inactive), regardless of the date of diagnosis, must be reported. Each case of cancer must be abstracted and reported separately.

Information about these previous (historical) primaries may be sketchy. The abstractor should attempt to complete an abstract with as much information as is available in the medical record.

Class of Case

The Class of Case reflects the facility's role in managing the cancer, whether the cancer is required to be reported by CoC, and whether the case was diagnosed after the program's Reference Date.

FCDS relies on accurate Class of Case coding

Documentation often lacking or insufficient in text

Some Registrars only want to abstract cases required by CoC

Florida Statute overrules voluntary reporting to CoC

Class of Case

Analytic Classes of Case

Initial diagnosis at reporting facility



00 Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere

10 Initial diagnosis at the reporting facility or in a staff physician's office AND part or all of first course Treatment or a decision not to treat was at the reporting facility, NOS.

If it is **not known** that the patient actually **went somewhere else**, code *Class of Case 10*

11 Initial diagnosis in staff physician's office AND part of first course treatment was done at the reporting facility


12 Initial diagnosis in staff physician's office AND all first course treatment or a decision not to treat was done at the reporting facility

13 Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.

Class of Case


Analytic Classes of Case

Initial diagnosis at reporting facility



- 14** Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility

Initial diagnosis elsewhere



- 20** Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS

- 21** Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility

- 22** Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility

Class of Case




Non-Analytic Classes of Case

Patient appears in person at reporting facility



- | | |
|----|--|
| 30 | Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only) NOTE: The 2010 FORDS Manual changed the definition Class of Case = 30 the CoC added a new component to what previously had been "consult only." The addition is for cases where the facility is part of the "staging workup after initial diagnosis elsewhere." These cases are "analytic" to FCDS and in Florida a "consult only" case only refers to a case where the facility provides a second opinion without additional testing. |
| 31 | Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care |
| 32 | Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence (active disease) |

Class of Case

33	Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (disease not active)
34	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility
35	Case diagnosed before program's Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility
36	Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility
37	Case diagnosed before program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility
38	Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death
<i>Patient does not appear in person at reporting facility</i> 	
40	Diagnosis AND all first course treatment given at the same staff physician's office
41	Diagnosis and all first course treatment given in two or more different staff physician offices

Class of Case

Non-Analytic Classes of Case


Patient appears in person at reporting facility



- | | |
|----|--|
| 42 | Non-staff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility) |
| 43 | Pathology or other lab specimens only |
| 49 | Death certificate only |
| 99 | Non-analytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases). |

Social Security Number


- SSN is a required data item
 - FCDS relies heavily on correct SSN in abstracts
 - Healthcare payments rely heavily on correct SSN on bill
 - AHCA only includes DOB and SNN – no names
-
- Partial SSN
 - SSN not available
 - SSN not accessible to me
 - How to locate SSN in medical record
 - Future of SSN in cancer registration and FCDS
 - What to do when AHCA SSN and Registry SSN don't match?



Inflammatory Carcinoma of Breast

- Inflammatory carcinoma of the breast is a clinico-pathologic entity characterized by diffuse erythema and edema (peau d'orange) of the breast, often without underlying mass.
- Inflammatory carcinoma is primarily a clinical diagnosis with skin changes that usually arise quickly in the affected breast.
- A biopsy is required to demonstrate cancer either within the dermal lymphatics or in the breast parenchyma itself.
- Involvement of dermal lymphatics alone does not indicate inflammatory carcinoma in the absence of clinical findings.
- Clinical findings should involve majority of the skin of breast.
- The term of inflammatory carcinoma should not be applied to a patient with neglected locally advanced cancer of the breast presenting late in the course of her disease.

Plasma Cell Neoplasm Staging



Plasma Cell Neoplasm Staging

Table 1: The Durie-Salmon Staging System for Multiple Myeloma

Stage	Hemoglobin	Calcium	Myeloma Protein	Bone Lesions
I ^a	>10 g/dL	Normal or ≤ 12 g/dL	IgG peak <5 g/dL IgA peak <3 g/dL Bence-Jones protein <4 g/24 h	None or solitary bone plasmacytoma only
II ^b	Not I or III	Not I or III	Not I or III	Not I or III
III ^c	<8.5 g/dL	>12 mg/dL	IgG peak >7 g/dL IgA peak >5 g/dL Bence-Jones protein >12 g/24 h	>3 lytic lesions

^a Stage I must demonstrate all of the criteria.

^b Stage II defined as all patients who do not qualify as Stage I or III.

^c Stage III must demonstrate one or more of the criteria.

Source: Reference 7.

Plasma Cell Neoplasm Staging

Collaborative Stage for TNM 7 - Revised 10/25/2011

MyelomaPlasmaCellDisorder

Plasma Cell Disorders including Myeloma

- 9731 Plasmacytoma, NOS (except C441, C690, C695-C696)
- 9732 Multiple myeloma (except C441, C690, C695-C696)
- 9734 Plasmacytoma, extramedullary (except C441, C690, C695-C696)
- Note 1: This schema was added in V0203. Originally these histologies were part of the HemeRetc schema.
- Note 2: AJCC does not define TNM staging for this site.

[CS Tumor Size](#) = 988

[CS Extension](#)

[CS Tumor Size/Ext Eval](#) = 9

[CS Lymph Nodes](#)

[CS Lymph Nodes Eval](#) = 9

[Regional Nodes Positive](#) = 99

[Regional Nodes Examined](#) = 99

[CS Mets at DX](#)

[CS Mets Eval](#) = 9

[CS Site-Specific Factor 1](#)

OBSOLETE - Janus Kinase 2 (JAK2) (also known as JAK2 Exon 12)

[CS Site-Specific Factor 2](#)

Durie-Salmon Staging System

[CS Site-Specific Factor 3](#)

Multiple Myeloma Terminology

[CS Site-Specific Factor 4](#) = 988

[CS Site-Specific Factor 5](#) = 988

[CS Site-Specific Factor 6](#) = 988

[CS Site-Specific Factor 7](#) = 988

[CS Site-Specific Factor 8](#) = 988

[CS Site-Specific Factor 9](#) = 988

[CS Site-Specific Factor 10](#) = 988

[CS Site-Specific Factor 11](#) = 988

[CS Site-Specific Factor 12](#) = 988

[CS Site-Specific Factor 13](#) = 988

[CS Site-Specific Factor 14](#) = 988

[CS Site-Specific Factor 15](#) = 988

[CS Site-Specific Factor 16](#) = 988

[CS Site-Specific Factor 17](#) = 988

[CS Site-Specific Factor 18](#) = 988

[CS Site-Specific Factor 19](#) = 988

[CS Site-Specific Factor 20](#) = 988

[CS Site-Specific Factor 21](#) = 988

[CS Site-Specific Factor 22](#) = 988

[CS Site-Specific Factor 23](#) = 988

[CS Site-Specific Factor 24](#) = 988

[CS Site-Specific Factor 25](#) = 988

Plasma Cell Neoplasm Staging

- **CS Extension**


- Note 1: **Osseous plasmacytomas are localized tumors occurring in the bone.** There may be soft tissue extension.

- Note 2: **Extraosseous (extramedullary) plasmacytomas are plasma cell neoplasms that arise in tissues other than bone.** The most common sites are the upper respiratory tract, the gastrointestinal tract, lymph nodes, bladder, central nervous system (CNS), breast, thyroid, testis and skin.

- Note 3: **Criteria for the diagnosis of multiple myeloma include:** presence of clonal bone marrow plasma cells or plasmacytoma, presence of an M-protein in serum and/or urine, and the presence of related organ or tissue impairment. Do not use this criteria to determine the diagnosis of multiple myeloma. Code according to histologic confirmation or physician statement according to the AJCC 7th edition.

- Note 4: **Multiple myeloma or plasma cell myeloma is a widely disseminated plasma cell neoplasm,** characterized by a single clone of plasma cells derived from B cells that grows in the bone marrow. **It is always coded to 810 or 820 for systemic involvement.**

Plasma Cell Neoplasm Staging


Code	Description
100	OBSOLETE DATA RETAINED V0203 Localized disease (single/solitary/unifocal/isolated/mono-ostotic), may be coded for: Plasmacytoma, NOS (M-9731/3)(solitary myeloma) Plasmacytoma, extramedullary (M-9734/3) (not occurring in bone)
110	Single plasmacytoma lesion WITHOUT soft tissue extension or unknown if soft tissue extension (9731)
200	Single plasmacytoma lesion WITH soft tissue extension (9731)
300	Single plasmacytoma lesion occurring in tissue other than bone (9734)
400	Multiple osseous or multiple extraosseous plasmacytoma lesions (9731, 9734)
500	Plasmacytoma, NOS (9731) Not stated if single or multiple, not stated if osseous or extraosseous
800	OBSOLETE DATA RETAINED V0203 Systemic disease (poly-ostotic): All histologies including those in 100
810	Plasma cell myeloma/multiple myeloma/myelomatosis (9732)
820	Myeloma, NOS Excludes plasma cell myeloma or multiple myeloma (see code 810)
	Unknown; extension not stated Primary tumor cannot be assessed Not documented in patient record

9
3
1
7

9732

9734

Unknown Primary/III-Defined Site



Unknown Primary/III-Defined Site

- **Rule H. Use the topography code provided when a topographic site is not stated in the diagnosis. This topography code should be disregarded if the tumor is known to arise at another site.**

**Head and Neck Equivalent Terms, Definitions, Charts, Tables and Illustrations
C000-C148, C300-C329**

(Excludes lymphoma and leukemia – M-9590 – 9989 and Kaposi sarcoma M9140)

When the point of origin cannot be determined, use a topography code for overlapping sites:

- **C02.8 Overlapping lesion of tongue**
- **C08.8 Overlapping lesion of major salivary glands**
- **C14.8 Overlapping lesion of lip, oral cavity, and pharynx.**

Unknown Primary/III-Defined Site

Site Title	Site Code	Histology Title	Histology Codes
Skin, Arm	C44.6	Carcinoma, Melanoma, Merkel Cell, Mycosis Fungoides, Cutaneous T-Cell Lymphoma of Arm	8010 8720-8970 8747 9700 9709
Soft Tissue, Arm	C49.1	Sarcoma	8800-8921
Peripheral Nerve, Arm	C47.1	Sarcoma	8800-8921
Bone, Arm	C40.3	Sarcoma (osteo)	9180-9194
Lymph Nodes, Arm	C77.3	Lymphoid Neoplasms	See Heme DB

First Course of Treatment

First course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence.

- Watch and Wait – If first course of treatment is to do nothing but watch and wait – **as soon as the patient has a change in status (rising PSA, clinical evidence of disease, etc.) – the patient has disease progression and the first course of treatment (watch and wait) is OVER.** Treatment given after the change in patient cancer status is subsequent TX.
- **Do not code ancillary drugs as treatment – use SEER*Rx**

Palliative Care or Palliative Treatment

The term “palliative” or “palliation” may be used in two different contexts: (a) as meaning non-curative and (b) as meaning the alleviation of symptoms. Either can be first course of treatment. Either can be subsequent treatment. Either can be end-of-life.

Some palliative treatments fall within the definition of cancer-directed treatment and some treat the patient but not the cancer.

Palliative treatment may qualify the patient as **analytic** if it is given as part of the planned first course of treatment.

Palliative treatment may qualify the patient as **non-analytic**, if it given as subsequent treatment for recurrence or progression.

Coding Surgery Fields Correctly

- Surgery of Primary Site
 - Do not code colostomy as 90
 - Do not code unknown if surgery performed as 99
 - Use best code available
- Scope of Regional Lymph Node Surgery
- Surgery of Other Regional or Distant Sites
- Reason No Surgery
- Date of Surgery – know what your vendor is sending FCDS
- Treatment Status – don't forget watch & wait/observation
- Surg/Rad Seq
- Surg/Systemic Seq

One More Webinar



Intended Audience:

- Physicians
- Nurse Practitioners
- Physician Assistants
- Nurses
- Dietitians
- Billers
- Coders
- Educators
- Office Managers
- Medical Assistants

To Register:

1. Go to:
<https://hsag.webex.com/hsag/onstage/g.php?t=a&d=255381497>
2. Click "Register."
3. On the registration form, enter your information and then click "Submit."

Tuesday

November 5, 2013

1 p.m. - 2 p.m ET - Noon - 1 p.m. CT

The Latest on Lung Cancer Screening

Speaker:

Robert A. Smith, PhD
American Cancer Society, Inc., Cancer Control Science Department



Dr. Robert A. Smith is a cancer epidemiologist and Senior Director, Cancer Screening, at the National Office of the American Cancer Society in Atlanta, Georgia, where he leads the development of cancer screening guidelines. His primary research interests are cancer epidemiology, evaluation of cancer prevention and early detection programs, multi-chronic disease models of preventive care, and quality assurance in the delivery of health services.

Dr. Smith serves on many international and national government and professional advisory committees and working groups, including the American College of Radiology Committee on Screening and Emerging Technologies; the American College of Radiology Commission on Breast Imaging; National Colorectal

References / Resources

Dryden M and Brogan K. Quality Control. Chapter 20 in Menck H, et al. *Central Cancer Registries: Design, Management and Use, second edition*. Kendall Hunt Publishing Co., 2007.

Hilsenbeck SG, et al. *Quality Control for Cancer Registries*. National Cancer Institute, U.S. Department of Health and Human Services, 1985.

Hilsenbeck SG. Quality Control. Chapter 7 in: Menck H, et al. *Central Cancer Registries: Design, Management and Use*. Harwood Academic Publishers, 1994.

Ross F. Quality Control of Cancer Registry Data. Chapter 21 in Menck H, et al. *Cancer Registry Management: Principles and Practice, second edition*. Kendall Hunt Publishing Co., 2004.

References / Resources

NAACCR Standards for Cancer Registries Volume III: Standards for Completeness, Quality, Analysis, and Management of Data, October 2004.

NPCR Educational Materials for Cancer Registrars

Volume 3: Data Editing and EDITS: Procedures for Central Registries

Volume 4: Coding and Visual Editing: Procedures for Central Registries

Volume 6: Audits: Casefinding and Reabstracting: Procedures for Central Registries

Unpublished materials provided by National Program of Cancer Registries

Questions

